Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: August 2011

2 - Progressive supranuclear palsy


1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–59.
2. Williams DR, Lees AJ, Wherrett JR, Steele JC. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology 2008; 70(7): 566–73.
3. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49(5): 1284–8.
4. Nath U, Ben-Shlomo Y, Thomson RG et al. The prevalence of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) in the UK. Brain 2001; 124(Pt 7): 1438–49.
5. Caparros-Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999; 354(9175): 281–6.
6. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006; 77(4): 468–73.
7. Ondo W, Warrior D, Overby A et al. Computerized posturography analysis of progressive supranuclear palsy: a case–control comparison with Parkinson’s disease and healthy controls. Arch Neurol 2000; 57(10): 1464–69.
8. Jankovic J, Friedman DI, Pirozzolo FJ, McCrary JA. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol 1990; 53: 293–304.
9. Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75(10): 1386–94.
10. Romano S, Colosimo C. Procerus sign in progressive supranuclear palsy. Neurology 2001; 57(10): 1928.
11. Jankovic J. Apraxia of lid opening. Mov Disord 1995; 10(5): 686–7.
12. Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I. “Applause sign” helps to discriminate PSP from FTD and PD. Neurology 2005; 64(12): 2132–3.
13. Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington’s disease. Mov Disord 2008; 23(16): 2307–11.
14. Sixel-Doring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med 2009; 10(4): 407–15.
15. Schmidt C, Herting B, Prieur S et al. Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord 2008; 23(14): 2083–9.
16. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130(Pt 6): 1552–65.
17. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47(1): 1–9.
18. Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb ClinNeurol 2008; 89: 461–73.
19. Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 189–201.
20. Ros R, Gomez Garre P, Hirano M et al. Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol 2005; 57(5): 634–41.
21. Stamelou M, de Silva R, Arias-Carrion O et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133(Pt 6): 1578–90.
22. Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000; 55(9): 1364–7.
23. Melquist S, Craig DW, Huentelman MJ et al. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500 288 single-nucleotide polymorphisms. Am J Hum Genet 2007; 80(4): 769–78.
24. Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 2002; 40(6): 559–64.
25. Stamelou M, Pilatus U, Reuss A et al. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab 2009; 29(4): 861–70.
26. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2002; 104(6): 583–91.
27. Hollerhage M, Matusch A, Champy P et al. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol 2009; 220(1): 133–42.
28. Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44(11): 2015–19.
29. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23(4): 394–400.
30. Josephs KA, Boeve BF, Duffy JR et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11(4): 283–96.
31. Mori H, Oda M, Komori T et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol 2002; 104(3): 273–8.
32. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001; 58(7): 1076–9.
33. Oba H, Yagishita A, Terada H et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64(12): 2050–55.
34. Seppi K, Schocke MF, Esterhammer R et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60(6): 922–7.
35. Padovani A, Borroni B, Brambati SM et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2006; 77(4): 457–63.
36. Boxer AL, Geschwind MD, Belfor N et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63(1): 81–6.
37. Mishina M, Ishii K, Mitani K et al. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand 2004; 110(2): 128–35.
38. Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28(4): 547–55.
39. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele–Richardson–Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57(3): 278–84.
40. Pirker W, Asenbaum S, Bencsits G et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15(6): 1158–67.
41. Sakakibara R, Hattori T, Tojo M, Yamanishi T, Yasuda K, Hirayama K. Micturitional disturbance in progressive supranuclear palsy. J Auton Nerv Syst 1993; 45(2): 101–06.
42. Borroni B, Malinverno M, Gardoni F et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008; 71(22): 1796–803.
43. Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 2010; 16(2): 142–45.
44. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991; 41(7): 986–91.
45. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57(3): 467–73.
46. Liepelt I, Gaenslen A, Godau J et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement 2010; 6(1): 70–4.
47. Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997; 3(4): 211–14.
48. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341(7): 543–4.
49. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72(3): 1327–30.
50. Stamelou M, Reuss A, Pilatus U et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23(7): 942–9.
51. Bergmann KJ, Salak VL. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14(4): 348–52.